Gilteritinib Versus Salvage Chemotherapy for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: A Phase 3, Randomized, Multicenter, Open-Label Trial in Asia

被引：4
|
作者：
Wang, Jianxiang [1 ]
Jiang, Bin [2 ]
Li, Jian [3 ]
Liu, Ligen [4 ]
Du, Xin [5 ]
Jiang, Hao [6 ]
Hu, Jianda [7 ]
Yuan, Menghe
Sakatani, Taishi [8 ]
Kadokura, Takeshi [9 ]
Takeuchi, Masato [9 ]
Izuka, Shunsuke [9 ]
Girshova, Larisa [10 ]
Tan, Jerome [11 ]
Bondarenko, Sergey N. [12 ]
Wong, Lily L. L. [13 ]
Khuhapinant, Archrob [14 ]
Martynova, Elena [15 ]
Hasabou, Nahla [16 ]
Tiu, Ramon V. [16 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol & Blood Dis Hosp, Natl Clin Res Ctr Blood Dis, State Key Lab Expt Hematol, Tianjin, Peoples R China
[2] Peking Univ Int Hosp, Dept Hematol, Beijing, Peoples R China
[3] Peking Union Med Coll Hosp, Dept Hematol, Beijing, Peoples R China
[4] Shanghai Tongren Hosp, Dept Hematol, Shanghai, Peoples R China
[5] Guangdong Prov Peoples Hosp, Dept Hematol, Guangzhou, Peoples R China
[6] Peking Univ Peoples Hosp, Dept Hematol, Beijing, Peoples R China
[7] Fujian Med Univ Union Hosp, Fujian Inst Hematol, Fuzhou, Fujian, Peoples R China
[8] Astellas Pharma Inc, Beijing, Peoples R China
[9] Astellas Pharma Inc, Tokyo, Japan
[10] Almazov Natl Med Res Ctr, St Petersburg, Russia
[11] Univ Malaysia Sarawak, Fac Med & Hlth Sci, Dept Med, Dept Hematol,Ampang Hosp Selangor, Sarawak, Malaysia
[12] State Med Univ, Clin Res Inst Pediat Hematol & Transplantat Name, St Petersburg, Russia
[13] Queen Elizabeth Hosp, Dept Hematol, Kota Kinabalu, Sabah, Malaysia
[14] Mahidol Univ, Fac Med Siriraj Hosp, Div Hematol, Dept Med, Bangkok, Thailand
[15] Skolkovo Inst Sci & Technol, Moscow, Russia
[16] Astellas Pharma Inc, Northbrook, IL USA
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-145436
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
695
引用
收藏
页数：4
相关论文
共 50 条
  • [11] Iadademstat and Gilteritinib for the Treatment of FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia: The Frida Study
    Fathi, Amir T.
    Braun, Theodore P.
    Ambinder, Alexander Joseph
    Borthakur, Gautam
    Redner, Robert L.
    Arevalo, Mabel
    Gutierrez, Sonia
    Limon, Ana
    Faller, Douglas V.
    BLOOD, 2023, 142
  • [12] Gilteritinib with or without venetoclax for relapsed/refractory FLT3-mutated acute myeloid leukaemia
    Kugler, Eitan
    Cohen, Inbar
    Amitai, Irina
    Ram, Ron
    Frisch, Avraham
    Nachmias, Boaz
    Canaani, Jonathan
    Moshe, Yakir
    Krayem, Baher
    Aumann, Shlomzion
    Henig, Israel
    Vainstein, Vladimir
    Shargian, Liat
    Ganzel, Chezi
    Yeshurun, Moshe
    Levi, Itay
    Raanani, Pia
    Akria, Luiza
    Ofran, Yishai
    Shimony, Shai
    Wolach, Ofir
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 205 (03) : 932 - 941
  • [13] A Phase I/II Study of Gilteritinib and Momelotinib for Patients with Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: A Trial in Progress
    Short, Nicholas J.
    Ravandi, Farhad
    Daver, Naval
    Dinardo, Courtney D.
    Borthakur, Gautam
    Kadia, Tapan M.
    Yilmaz, Musa
    Issa, Ghayas C.
    Abramova, Regina
    Garza, Araceli Isabella
    Kantarjian, Hagop M.
    Abbas, Hussein A.
    BLOOD, 2024, 144
  • [14] Gilteritinib and Venetoclax for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia - a Real-World Multicenter Retrospective Study
    Kugler, Eitan
    Cohen, Inbar
    Ram, Ron
    Canaani, Jonathan
    Amitai, Irina
    Shargian, Liat
    Nachmias, Boaz
    Krayem, Baher
    Frisch, Avraham
    Levi, Itay
    Akria, Luiza
    Raanani, Pia
    Wolach, Ofir
    Kugler, Eitan
    BLOOD, 2023, 142
  • [15] Phase 3, Open-Label, Randomized Study of Gilteritinib and Azacitidine Vs Azacitidine for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in Patients Ineligible for Intensive Induction Chemotherapy
    Wang, Eunice S.
    Montesinos, Pau
    Minden, Mark D.
    Lee, Je-Hwan
    Heuser, Michael
    Naoe, Tomoki
    Chou, Wen-Chien
    Laribi, Kamel
    Esteve, Jordi
    Altman, Jessica K.
    Havelange, Violaine
    Watson, Anne-Marie
    Patkowska, Elzbieta
    Liu, Shufang
    Wu, Ruishan
    Philipose, Nisha
    Hill, Jason E.
    Gill, Stanley
    Rich, Elizabeth Shima
    Tiu, Ramon V.
    BLOOD, 2021, 138
  • [16] Gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia: a regional analysis of COMMODORE in China, South-East Asia, and Russia
    Jiang, Bin
    Li, Jian
    Liu, Ligen
    Du, Xin
    Jiang, Hao
    Hu, Jianda
    Zeng, Xiaoxi
    Sakatani, Taishi
    Kosako, Masanori
    Deng, Yaru
    Girshova, Larisa
    Bondarenko, Sergey
    Lee, Lily Wong Lee
    Khuhapinant, Archrob
    Martynova, Elena
    Hasabou, Nahla
    Wang, Jianxiang
    ANNALS OF HEMATOLOGY, 2025,
  • [17] Cost-Effectiveness Analysis of Gilteritinib Versus Salvage Chemotherapy (SC) for the Treatment of Relapsed or Refractory (R/R) FLT3-Mutated (FLT3mut+) Acute Myeloid Leukemia (AML)
    Zeidan, Amer M.
    Qi, Cynthia Z.
    Pandya, Bhavik J.
    Garnham, Andy
    Yang, Hongbo
    Shah, Manasee V.
    BLOOD, 2019, 134
  • [18] Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated relapsed/refractory acute myeloid leukemia: results from the phase 3 ADMIRAL trial
    Perl, A. E.
    Martinelli, G.
    Cortes, J. E.
    Neubauer, A.
    Berman, E.
    Paolini, S.
    Montesinos, P.
    Baer, M. R.
    Larson, R. A.
    Ustun, C.
    Fabbiano, F.
    Di Stasi, A.
    Stuart, R.
    Olin, R.
    Kasner, M.
    Ciceri, F.
    Chou, W. -C.
    Podoltsev, N.
    Recher, C.
    Yokoyama, H.
    Hosono, N.
    Yoon, S. -S.
    Lee, J. -H.
    Pardee, T.
    Fathi, A. T.
    Liu, C.
    Liu, X.
    Bahceci, E.
    Levis, M. J.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 295 - 295
  • [19] Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial
    Smith, Catherine C.
    Levis, Mark J.
    Perl, Alexander E.
    Martinelli, Giovanni
    Neubauer, Andreas
    Berman, Ellin
    Montesinos, Pau
    Baer, Maria R.
    Larson, Richard A.
    Chou, Wen-Chien
    Yokoyama, Hisayuki
    Recher, Christian
    Yoon, Sung-Soo
    Hill, Jason E.
    Rosales, Matt
    Bahceci, Erkut
    BLOOD, 2019, 134
  • [20] GILTERITINIB SIGNIFICANTLY PROLONGS OVERALL SURVIVAL IN PATIENTS WITH FLT3-MUTATED RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA: RESULTS FROM THE PHASE 3 ADMIRAL TRIAL
    Perl, A. E.
    Martinelli, G.
    Cortes, J. E.
    Neubauer, A.
    Berman, E.
    Paolini, S.
    Montesinos, P.
    Baer, M. R.
    Larson, R. A.
    Ustun, C.
    Fabbiano, F.
    Di Stasi, A.
    Stuart, R.
    Olin, R.
    Kasner, M.
    Ciceri, F.
    Chou, W.
    Podoltsev, N.
    Recher, C.
    Yokoyama, H.
    Hosono, N.
    Yoon, S.
    Pardee, J. Lee T.
    Fathi, A. T.
    Liu, C.
    Liu, X.
    Bahceci, E.
    Levis, M. J.
    HAEMATOLOGICA, 2019, 104 : 2 - 2
12345